Form 4: Rezolute Director Gains 21,000 RSUs, 12,000 Options

Rezolute, Inc. Director Philippe Fauchet acquired 21,000 restricted stock units and 12,000 stock options, vesting December 1, 2026.

Summary

• Philippe Fauchet, a Director of Rezolute, Inc. (RZLT), acquired 21,000 common shares in the form of Restricted Stock Units (RSUs) on November 19, 2025.
• These 21,000 RSUs were granted at a price of $0 and are scheduled to fully vest on December 1, 2026.
• Following this transaction, Philippe Fauchet beneficially owns 55,500 common shares.
• Additionally, Philippe Fauchet acquired 12,000 Director Stock Options (right to buy) on November 19, 2025.
• These options have an exercise price of $10.16 per share and fully vest on December 1, 2026, with an expiration date of November 19, 2035.
• Following this transaction, Philippe Fauchet beneficially owns 12,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The filing reports routine equity compensation for a director, which is generally positive as it aligns management's interests with shareholders. It does not contain any negative or unexpected information.

Positives

• The acquisition of restricted stock units and stock options by a director indicates increased alignment of management's interests with those of shareholders.
• Equity grants are a common incentive for retaining key personnel and motivating performance.

Future Outlook

The vesting schedule for the restricted stock units and stock options on December 1, 2026, suggests a future increase in the director's direct beneficial ownership of common shares and exercisable options, aligning long-term interests with company performance.

Industry Context

Equity compensation, including restricted stock units and stock options, is a standard practice across various industries for compensating and incentivizing directors and executives, fostering alignment with shareholder value creation.

Comparison to Industry Standards

• The grant of restricted stock units and stock options to a director is a common form of equity compensation, widely used in the biotechnology and pharmaceutical sectors to attract and retain talent.
• The vesting schedule and option terms appear consistent with typical director compensation packages designed to promote long-term commitment and performance.

Corporate Governance

Related Party Transactions

• The grant of 21,000 restricted stock units and 12,000 stock options to Philippe Fauchet, a Director of Rezolute, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The equity grants align the director's financial interests with shareholder value creation, potentially leading to more focused decision-making aimed at increasing share price.
• Employees: While not directly impacting employees, such compensation practices for directors can set a precedent for broader equity incentive programs within the company.

Next Steps

• The restricted stock units and stock options will fully vest on December 1, 2026, at which point the director will have full ownership of the shares and exercisability of the options.

Key Dates

Recommendation

This Form 4 reports routine equity compensation for a director, which is a standard practice to align management interests with shareholders. It does not provide new fundamental information to alter an investment thesis, thus a 'hold' recommendation remains appropriate based solely on this filing.

Keywords

Rezolute, RZLT, Form 4, Insider Transaction, Director Compensation, Restricted Stock Units, Stock Options, Equity Grant, Philippe Fauchet